AstraZeneca

The Disconnect in British Equities Investors looking for value often overlook the profound structural differences within the UK market. While the blue-chip FTSE 100 commands the headlines, it behaves more like a global proxy. It is heavily weighted toward multinational giants that earn in foreign currencies. The real story of the domestic economy lies elsewhere, currently trading at historical discounts. Global Giants versus Domestic Reality Multinational giants like Shell and HSBC dominate the FTSE 100. These companies insulate themselves from UK-specific economic headwinds by generating the majority of their revenues overseas. Conversely, the FTSE 250 serves as the true backbone of the domestic economy. This index contains mid-sized British businesses, including retailers like Frasers Group and housebuilders like Bellway. These domestic firms bear the direct brunt of local market sentiment. Valuation Metrics Reach Historic Lows Data from MAIA Asset Management reveals an extreme disconnect. The FTSE 250 forward price-to-earnings and price-to-sales ratios have plunged to levels not seen since the 2008 global financial crisis. Crucially, this drop in valuation is not driven by failing businesses. Earnings per share have actually improved. We are seeing a rare scenario where companies are making more money, yet their share prices are falling due to negative market sentiment. The Catch-Up Potential This pricing inefficiency caught the attention of investment bank UBS, which highlighted the index's rare combination of affordability and growth. Although the mid-cap index rose over 6% in 2025, it lagged the blue-chip index significantly. It remains well below its September 2021 all-time high, presenting a compelling entry point for patient wealth builders.